Days
Hrs
Mins
REGISTER NOW
JOIN MAILING LIST

Venue

SHERATON GRAND SYDNEY HYDE PARK

161 Elizabeth Street
Sydney NSW 2000
W: https://www.marriott.com/en-us/hotels/sydsi-sheraton-grand-sydney-hyde-park 

The 8th Annual Scientific Meeting 2022 will be held at the Sheraton Grand Sydney Hyde Park. which combines the latest in technology and style in Sydney’s CBD to create refined spaces ideal for the 2022 ASM.

Sheraton Grand Sydney Hyde Park is one of Sydney’s most desirable event destinations. Natural light, high-speed Wi-Fi, outdoor terraces and dedicated concierge services ensure productive meetings any time of year.

The expert culinary team crafts custom menus for the meeting. With five on-site venues and in-room dining, you’re never far from a delicious meal or post-meeting snack.

Centrally located in the heart of Sydney’s retail and business districts, Sheraton Grand Sydney is the perfect launch pad for exploring Sydney’s iconic attractions, open-air shopping malls, fine restaurants, cafes, bars and destinations that define this vibrant city.

DON'T MISS OUT ON IMPORTANT UPDATES

JOIN MAILING LIST
ORGANISER

MCI Australia
Level 11, 87 Wickham Terrace
Spring Hill QLD 4000

P: +61 7 38585400

E: info@anzchog2022.com

STAY IN TOUCH
Join mailing list

© 2022 ASM 2022. All rights reserved.

Designed and built by MCI Australia

Jazz Pharmaceuticals is a global Biopharmaceutical Company whose purpose is to transform the lives of patients and their families through innovation. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options so they can live their lives more fully.

We have a diverse portfolio of marketed medicines and novel product candidates, from early- to latestage development, in Neuroscience and Haematology/Oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Jazz Pharmaceuticals has employees around the globe including Australia and New Zealand, serving patients in nearly 75 countries

Medical Information
Phone: 1800577422
Email: medinfo-apac@jazzpharma.com

Adverse event
Phone: 1800577422
Email: AEReporting@jazzpharma.com


To report a Product Complaint, please email:
productcomplaints@jazzpharma.com

Dr Robert Battisti

Children’s Hospital Westmead

Dr Battisti is a Clinical Psychologist and Researcher at the Cancer Centre for Children at the Children’s Hospital at Westmead, and an Honorary Research Associate at the University of Sydney. Dr Battisti completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre at the University of Sydney. Dr Battisti is also on the Board of Directors for the Australian Clinical Psychology Association (ACPA). His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in paediatric cancer including childhood cancer survivorship.

A/Prof Antoinette Anazodo

Kids Cancer Centre, Sydney Children’s Hospital

A/Professor Anazodo is the lead clinician for Youth Cancer Services in NSW and the ACT, and the Director of the Adolescent and Young Adult Cancer Service encompassing Sydney Children’s Hospital and Prince of Wales Hospital. She leads the Future Fertility research program and has been instrumental in making fertility preservation accessible for oncology patients all around Australia, by developing Medicare item numbers for public funding. A/Professor Anazodo chairs the Australian AYA fertility preservation group, which leads the development of guidelines in the field of oncofertility. She has over 100 publications in the fields of adolescent medicine and oncofertility, and is a principle investigator on multiple successful grants from both the NHMRC and Cancer Australia. A/Professor Anazodo has received a number of awards for her work including a NSW Premiers award in 2018 and a Medal of the Order of Australia in 2021.

Dr Justin Baker

St Jude Children’s Research Hospital

Dr Baker is the Division Chief of Quality of Life and Palliative Care at St. Jude Children’s Research Hospital, Memphis, TN, USA. He is trained in paediatric haematology/oncology, as well as Hospice and Palliative Medicine. Dr Baker is a world leader in paediatric palliative care and quality of life, with over 100 publications in the field. His research focuses on integrating palliative care into the ongoing care of children with cancer, the ethical consideration of early phase trials, and paediatric palliative care in developing countries. He was awarded the AAHPM Inspirational Leader in Hospice and Palliative Medicine in 2014, and the St. Jude Communicator of the Year in 2017. Dr Baker has led the development of guidelines in paediatric palliative care and quality of life that have been implemented in centres throughout the world, and has been an invited speaker at paediatric oncology and palliative care conferences across the globe.

Dr Robert Battisti

Children’s Hospital Westmead

Dr Battisti is a Clinical Psychologist and Researcher at the Cancer Centre for Children at the Children’s Hospital at Westmead, and an Honorary Research Associate at the University of Sydney. Dr Battisti completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre at the University of Sydney. Dr Battisti is also on the Board of Directors for the Australian Clinical Psychology Association (ACPA). His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in paediatric cancer including childhood cancer survivorship.

Prof Paul Monagle

University of Melbourne

Professor Monagle is an internationally renowned paediatric haematologist and haemato-pathologist. He is a Professor of Paediatrics at the University of Melbourne, a clinical Haematologist at the Kids Cancer Centre, Sydney Children’s Hospital, and an Honorary Fellow and Group Leader in Haematology Research at the Murdoch Children’s Research Institute. Professor Monagle is a world expert on thrombosis and coagulation, with over 300 publications in the field of paediatric haematology. His research group holds multiple NHMRC grants and is currently leading work into COVID-19 associated thrombosis. Professor Monagle was awarded the Outstanding Research Award in Paediatric Cardiology by the American Heart Association in 2008, and delivered the Barry Firkin Oration for the Thrombosis & Haemostasis Society of Australia and New Zealand in 2018. He has played a key role in designing multiple international multi-centre trials, and been an invited speaker at haematology conferences across the globe.

Prof Marcus Vowels

Professor Vowels is a renowned early leader of the paediatric oncology and haematology disciplines in Australia. Professor Vowels established the first bone marrow transplant program in Australia at the then Prince of Wales Children’s Hospital, now Sydney Children’s Hospital in Randwick, NSW. Professor Vowels established the Australian Cord Blood Bank and was a founding trustee of the Australian Cord Blood Foundation. Professor Vowels has over 100 peer reviewed publications, he was the founding member of a number of editorial boards of discipline specific journals and is the author of multiple book chapters. Professor Vowels was the President of the Australian and New Zealand Children’s Cancer Study Group from 1990 to 1994, and was awarded a Member of the Order of Australia (AM) for his service to medicine, particularly in the fields of childhood leukaemia and cancer.

Annabel Crabb

ABC Journalist

Annabel Crabb is one of Australia’s most beloved journalists. She is an ABC writer and presenter who has covered Australian politics for 20 years but also is nationally well-known for her insightful and humorous analysis on gender and current affairs. 

Annabel recently created and presented the ground breaking Ms Represented, unearthing stories from the 100 years of women in Australian parliaments. For the ABC, she has also devised and presented six seasons of the enormously popular Kitchen Cabinet, and “The House with Annabel Crabb – the fly-on-the-wall documentary on Australian Parliament.” She also presents the ABC’s hit culinary history series Back In Time For Dinner, and co-stars in Tomorrow Tonight with Charlie Pickering.

With friend and ABC colleague Leigh Sales, Australia’s pre-eminent current affairs journalist, Annabel hosts the top-rating podcast Chat 10 Looks 3. Their first book together, Well Hello, was published in September 2021.

Annabel is an avid baker and proud mother of three.

Bayer is a global enterprise with core competencies in healthcare and agriculture. Through science and innovation, the company is committed to the lives of people impacted by cancer. Bayer’s oncology research prioritises cutting-edge science across a range of therapeutic platforms to give patients and clinicians a multitude of options in the fight against cancer.

For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. As we move towards precision medicinein pediatric cancer, we have only just begun to discover the true impact of genomics. Learn how Illumina technologies is enabling novel insights into childhood cancer risk and treatment. Visit: https://sapac.illumina.com/destination/Precision-Medicine-in-Pediatric-Cancers.html

We are a dynamic, global biopharmaceutical company focused on oncology and rare disease, continuously striving to confront gaps in patient care. EUSA Pharma is committed to deliver solutions that can have a meaningful effect on life, helping patients across a range of therapy areas. We are continuously looking for new opportunities to confront current gaps in patient care. Our ambition and entrepreneurial culture drive us to explore, acquire and in-license products that we believe can bring about real change for patients.

Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that is committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development.

Worldwide approximately 25% of branded product turnover is reinvested into research and development through the Servier Foundation, with half of that investment dedicated to research to help fight cancer.

Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier Australia is also home to the Asia-Pacific clinical trial hub.

Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology

Information coming soon.

The Robert Connor Dawes (RCD) Foundation was created in June 2013 in the memory of Robert ‘Connor Dawes’ who lost his 16-month battle with an ependymoma brain tumour at just 18 years of age. The RCD Foundation works to support brain matters projects in the areas of research, care and development – to fund the science to fight paediatric brain cancer and support patients in the meantime.

The Foundation operates in Australia and the US, and to date has invested $3.45M into paediatric brain cancer research, funding basic science and translational projects, as well as capacity building grants through fellowships, scholarships and travel grants. It has also leveraged another $10M, leading collaborative research initiatives. In addition to funding and partnering with Australian research institutes and Foundations, RCD is also active member of the Child’s Brain Tumour Network (CBTN), Paediatric Neuro-Oncology Consortium (PNOC) and the Collaborative Ependymoma Research Network (CERN). We leverage our research investments through partnering with like-minded and passionate organisations to continue to battle paediatric brain cancer.

Our history
The Kids’ Cancer Project is an independent national charity supporting childhood cancer research. Since 1993, the charity has contributed more than $50 million dollars to scientific research projects to help children with many different types of cancer.

Our Goal
Mission: To support bold scientific research that has the greatest chance of clinical success in the improvement of treatments of childhood cancers.

Vision: One hundred per cent survival for children with cancer while eradicating the harmful impacts treatment can bring.

What we stand for
Science: We believe the only way to improve outcomes for kids with cancer is through advances in medical research.

Solutions: Our research priorities reflect our focus on finding better treatments, building research capabilities and supporting survivorship programs.

Survival: Our founder, Col Reynolds OAM, made a promise
to never give up until a cure is found.

Information coming soon.

Information coming soon.

Join the ANZCHOG ASM mailing list

Stay informed with the latest updates
* indicates required